Investor List:

Top Therapeutics Series B Investors in Boston / New England (17)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Manufacturing (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Scott Biller, Venture Partner at GV (Google Ventures)
Scott Biller
GV (Google Ventures)·Venture Partner
Sweet spot: $25.0M
Range: $250K - $50.0M
Investors in Boston (MA)
Photo of Wes Schifone, Scout at CRV
Wes Schifone
CRV·Scout
Sweet spot: $50K
Range: $25K - $100K
Investors in Boston (MA)
Investors in Web3/Blockchain (Series B), Investors in Consumer Health (Series B), Investors in Web3/Crypto (Series B), Investors in Consumer Health (Series A), Investors in Web3/Blockchain (Seed), Investors in Web3/Blockchain (Series A), Investors in Consumer Health (Seed), Investors in Web3/Crypto (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in Web3/Crypto (Seed), Investors in Web3/Blockchain (Seed), Investors in Consumer Health (Seed), Investors in Web3/Crypto (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Web3/Blockchain (Series A), Investors in Consumer Health (Series A), Investors in Web3/Crypto (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Web3/Blockchain (Series B), Investors in Consumer Health (Series B), Investors in Web3/Crypto (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Wellness & Fitness (Seed), Investors in Wellness & Fitness (Series B), Investors in Digital Health (Series B), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Seed), Investors in Wellness & Fitness (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Cavin Mozarmi, Senior Associate at REMUS Capital
Cavin Mozarmi
REMUS Capital·Senior Associate
Sweet spot: $15.0M
Range: $10.0M - $20.0M
Investors in Boston (MA)
Investors in Enterprise (Series B), Investors in FinTech (Series B), Investors in SaaS (Series B), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in FinTech (Seed), Investors in Enterprise (Seed), Investors in SaaS (Seed), Investors in Enterprise (Series A), Investors in FinTech (Series A), Investors in SaaS (Series A), Investors in Enterprise (Series B), Investors in FinTech (Series B), Investors in SaaS (Series B), Investors in Boston / New England (Other Lists), Investors in DeepTech (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Pre-seed), Investors in Enterprise (Pre-seed), Investors in SaaS (Pre-seed), Investors in Enterprise (Pre-seed), Investors in FinTech (Pre-seed), Investors in SaaS (Pre-seed), Investors in FinTech (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in SaaS (Series A), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in SaaS (Seed)
Photo of Derek DiRocco, Partner at RA Capital
Derek DiRocco
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Jake Simson, Partner at RA Capital
Jake Simson
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Reza Halse, Partner at RA Capital
Reza Halse
RA Capital·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Zach Scheiner, Principal at RA Capital
Zach Scheiner
RA Capital·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)